FX005
/ Pacira
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 06, 2020
The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
(PubMed, Curr Med Res Opin)
- "Pivotal trials for three approved ATTR-PN treatments, tafamidis (Fx-005), patisiran (APOLLO), and inotersen (NEURO-TTR), were compared in terms of study design, baseline population characteristics, outcome definitions, and baseline risk. An NMA of ATTR-PN treatments was not feasible, given the observed cross-trial heterogeneity. This decision highlights the importance of careful consideration for clinical heterogeneity that may threaten the validity of indirect comparisons."
Clinical • Heterogeneity • Journal
1 to 1
Of
1
Go to page
1